IONS — Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Q2 Revenues: $268 million, up 56% year-over-year.
• Year-to-Date Revenues: $514 million, a 69% increase compared to the same period last year, excluding a $280 million one-time payment from the previous year.
• Commercial Revenue: $119 million in Q2, a 15% increase; $226 million year-to-date, up 27%.
• TRYNGOLZA Sales: $5 million in Q2 and $32 million year-to-date, impacted by a reduction in wholesale acquisition cost (WAC) effective April 1.
• DAWNZERA Sales: $26 million in Q2, a 63% increase from Q1.
• Cash Position: $2.1 billion at the end of Q2.
• Operating Expenses: Expected to increase in the low teens percentage range compared to last year.
• Non-GAAP Operating Loss: Projected between $425 million and $475 million for 2026.

2. Strategic Updates and Business Highlights

• TRYNGOLZA Approval: Launched as the first FDA-approved treatment for severe hypertriglyceridemia (sHTG), with early prescription momentum and strong physician engagement.
• DAWNZERA Growth: Continues to capture market share in hereditary angioedema (HAE) prophylaxis, with positive feedback from healthcare providers (HCPs).
• Pipeline Development:
  • Zilganersen for Alexander disease is on track for a September 22 PDUFA date.
  • Obudanersen for Angelman syndrome completed enrollment in Phase III REVEAL study.
  • ION337 for Dravet syndrome initiated clinical development.
• Partnerships: Bepirovirsen for chronic hepatitis B is on track for global launch, with a PDUFA date of October 26.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected between $875 million and $900 million, with expectations for TRYNGOLZA and DAWNZERA to contribute significantly.
• TRYNGOLZA Sales Forecast: Expected to reach $100 million to $110 million for the full year, with a return to growth anticipated in the second half.
• DAWNZERA Sales Forecast: Expected to reach $110 million to $120 million for the full year.
• Cash Flow Breakeven Goal: Targeted for 2028.

4. Bad News, Challenges, or Points of Concern

• Eplontersen Study Disappointment: The CARDIO-TTRansform Phase III study did not meet its primary efficacy endpoint, which may impact future strategies and profitability.
• Reimbursement Challenges: Initial lack of dedicated ICD-10 codes for sHTG may create barriers for physicians in prescribing TRYNGOLZA.
• Competition: While TRYNGOLZA is positioned well, concerns about competition from other therapies like Arrowhead's product in FCS remain.

5. Notable Q&A Insights

• Early Adoption of TRYNGOLZA: Driven by previous prescribers of FCS, with a mix of patients on existing therapies and new starts. The process for prescription approval is still evolving.
• Reimbursement Landscape: Coverage for TRYNGOLZA is progressing well, but initial approvals are primarily through medical exceptions.
• Market Dynamics: DAWNZERA is seeing strong growth, with positive feedback from HCPs and an increasing share of the switch market.
• Future Pipeline: The company is optimistic about the potential of ION775 and its differentiated profile, aiming for convenience in dosing while maintaining efficacy.

Overall, Ionis Pharmaceuticals is experiencing strong revenue growth and positive momentum in its product launches, despite some challenges in the competitive landscape and regulatory hurdles. The company remains focused on executing its strategic initiatives and advancing its pipeline.